financetom
Business
financetom
/
Business
/
Zetwerk enters unicorn club; raises $150 million in equity round led by D1 Capital Partners
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Zetwerk enters unicorn club; raises $150 million in equity round led by D1 Capital Partners
Aug 23, 2021 2:59 PM

Custom manufacturing platform Zetwerk has raised a $150 million equity round led by New York-based D1 Capital Partners. New investors Avenir and IIFL also participated in the round, along with some existing investors.

Also Read: 26 unicorns and counting: A look at India's billion dollar startups of 2021

The latest round values Zetwerk at $1.33 billion, making it the latest entrant to the unicorn club. Zetwerk offers manufacturing solutions across a diverse range of products, from items like steel pipes to complex products like aircraft engine components, as well consumer products like apparel, home appliances, audio-visual electronics.

Also Read: Indian startups raised $6.5 billion funding in Q2 2021, 11 new unicorns created: Report

Its customers include General Electric, Larsen & Toubro, Indian Space Research Organization, among others. To know more about the fundraise, Startup Street spoke to Amrit Acharya, co-founder & CEO of Zetwerk.

Also Read: Best of Young Turks: Naren Gupta predicted tech startup boom in 2017; today India has 26 unicorns

Watch video for more.

(Edited by : Bivekananda Biswas)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Spectral Medical Says 105 Patients Now Enrolled in Tigris Trial
Spectral Medical Says 105 Patients Now Enrolled in Tigris Trial
May 6, 2024
08:16 AM EDT, 05/06/2024 (MT Newswires) -- Spectral Medical ( EDTXF ) , which is advancing therapeutic options for sepsis and septic shock, on Monday provided an update on its Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (PMX) in a trial of adults treated for endotoxemia and septic shock. The company reports that...
Block Plans $1.5 Billion Senior Notes Offering
Block Plans $1.5 Billion Senior Notes Offering
May 6, 2024
08:18 AM EDT, 05/06/2024 (MT Newswires) -- Block (SQ) said Monday it plans a private placement of $1.5 billion in senior notes. The company and the purchasers have yet to set the interest rate, redemption provisions, maturity date, and other terms of the notes. Block intends to use the net proceeds from this offering for general corporate purposes, which may...
LSL Pharma to Acquire Quebec Competitor for $2.5 Million to Expand Natural-Product Offerings
LSL Pharma to Acquire Quebec Competitor for $2.5 Million to Expand Natural-Product Offerings
May 6, 2024
08:18 AM EDT, 05/06/2024 (MT Newswires) -- LSL Pharma Group ( LPGIF ) on Monday said it will acquire a rival pharmaceutical manufacturer for $2.5 million in cash to expand its contract-manufacturing of natural health products. LSL identified the company only as a Quebec-based competing contract drug manufacturer (CDMO) specialized in the formulation, production, and marketing of natural products. LSL...
Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition
Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition
May 6, 2024
May 6 (Reuters) - Gossamer Bio ( GOSS ) said on Monday it will collaborate with Italian drugmaker Chiesi Group to develop and commercialize its therapy seralutinib in multiple indications related to high blood pressure due to constriction of lung arteries. The therapy is currently in late-stage development for the treatment of pulmonary arterial hypertension (PAH), which affects about 40,000...
Copyright 2023-2026 - www.financetom.com All Rights Reserved